374 related articles for article (PubMed ID: 16627561)
1. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.
Groskopf J; Aubin SM; Deras IL; Blase A; Bodrug S; Clark C; Brentano S; Mathis J; Pham J; Meyer T; Cass M; Hodge P; Macairan ML; Marks LS; Rittenhouse H
Clin Chem; 2006 Jun; 52(6):1089-95. PubMed ID: 16627561
[TBL] [Abstract][Full Text] [Related]
2. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
Shen M; Chen W; Yu K; Chen Z; Zhou W; Lin X; Weng Z; Li C; Wu X; Tao Z
Exp Mol Pathol; 2011 Feb; 90(1):97-100. PubMed ID: 20970419
[TBL] [Abstract][Full Text] [Related]
4. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.
Sokoll LJ; Ellis W; Lange P; Noteboom J; Elliott DJ; Deras IL; Blase A; Koo S; Sarno M; Rittenhouse H; Groskopf J; Vessella RL
Clin Chim Acta; 2008 Mar; 389(1-2):1-6. PubMed ID: 18061575
[TBL] [Abstract][Full Text] [Related]
5. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
6. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Iwata T; Kawauchi A; Miki T; Fors Z
Int J Urol; 2011 Mar; 18(3):200-5. PubMed ID: 21332814
[TBL] [Abstract][Full Text] [Related]
8. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
[TBL] [Abstract][Full Text] [Related]
9. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
10. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
11. [Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].
Vlaeminck-Guillem V; Campos-Fernandes JL; Champetier D; Chikh K; Decaussin-Petrucci M; Devonec M; Gobeaux N; Paparel P; Perrin P; Rodriguez-Lafrasse C; Ruffion A
Ann Biol Clin (Paris); 2011; 69(1):31-9. PubMed ID: 21463993
[TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
13. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.
Salagierski M; Mulders P; Schalken JA
Anticancer Res; 2013 Feb; 33(2):553-7. PubMed ID: 23393348
[TBL] [Abstract][Full Text] [Related]
14. Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
De Luca S; Passera R; Bollito E; Milillo A; Scarpa RM; Papotti M; Coda R; Randone DF
Anticancer Res; 2013 Oct; 33(10):4657-62. PubMed ID: 24123045
[TBL] [Abstract][Full Text] [Related]
15. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
16. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.
Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB
Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926
[TBL] [Abstract][Full Text] [Related]
17. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
Hessels D; Klein Gunnewiek JM; van Oort I; Karthaus HF; van Leenders GJ; van Balken B; Kiemeney LA; Witjes JA; Schalken JA
Eur Urol; 2003 Jul; 44(1):8-15; discussion 15-6. PubMed ID: 12814669
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
[TBL] [Abstract][Full Text] [Related]
19. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting.
Shappell SB; Fulmer J; Arguello D; Wright BS; Oppenheimer JR; Putzi MJ
Urology; 2009 Feb; 73(2):363-8. PubMed ID: 18995890
[TBL] [Abstract][Full Text] [Related]
20. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
